文献速递前列腺癌

通过转移性前列腺癌循环肿瘤细胞全外显子测序可及且独特地洞察转移灶突变内容

An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2019-01-04

研究开发三种循环肿瘤细胞(CTC)分离策略并在单细胞水平分离CTC,对11例患者的179份CTC样本及配对转移灶活检行全基因组扩增,对7例患者的34份CTC样本行全外显子测序;发现CTC与配对转移灶共享体细胞突变,并可识别CTC独有突变及不同表型CTC间的系统发育关系。

要点

  • CTC与配对转移灶活检共享的体细胞突变多见于上皮型CTC且呈复发性。
  • 在2例深入分析患者中,少量CTC即可代表配对转移灶活检中一半至三分之一的突变。
  • CTC独有突变见于上皮型和非上皮型CTC,41%的CTC独有突变被预测对蛋白功能有有害影响。

核心结论

  • CTC可提供对转移灶突变多样性的独特洞察,并揭示配对转移灶活检中未被诊断的基因组异常。

研究设计与样本

  • 研究采用三种分离策略(滤膜激光捕获显微切割、自种子微孔芯片和荧光激活细胞分选)在单细胞水平捕获具有不同上皮和间质表型的CTC。
  • 对来自11例患者的179份CTC样本、配对转移灶活检和阴性对照行全基因组扩增及质控;除1例外所有患者均接受过恩扎卢胺或阿比特龙治疗。
  • 对7例患者的34份CTC样本、转移灶活检和阴性对照行全外显子测序。

主要发现

  • CTC全外显子测序在10×深度覆盖百分比、等位基因脱扣和未覆盖区域方面进行了严格质控。
  • 共享突变主要见于上皮型CTC且呈复发性;在2例深入分析患者中,少量CTC即可代表配对转移灶活检中一半至三分之一的突变。
  • CTC独有突变见于上皮型和非上皮型CTC,涉及细胞骨架、侵袭、DNA修复和癌症驱动基因;41%的CTC独有突变被预测对蛋白功能有有害影响。
  • 研究证据了不同表型CTC之间的系统发育关系。

关键数值与推荐

  • 原文未报告指南或共识推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genomic analysis of circulating tumor cells (CTCs) could provide a unique and accessible representation of tumor diversity but remains hindered by technical challenges associated with CTC rarity and heterogeneity. OBJECTIVE: To evaluate CTCs as surrogate samples for genomic analyses in metastatic castration-resistant prostate cancer (mCRPC). DESIGN, SETTING, AND PARTICIPANTS: Three isolation strategies (filter laser-capture microdissection, self-seeding microwell chips, and fluorescence-activated cell sorting) were developed to capture CTCs with various epithelial and mesenchymal phenotypes and isolate them at the single-cell level. Whole-genome amplification (WGA) and WGA quality control were performed on 179 CTC samples, matched metastasis biopsies, and negative controls from 11 patients. All patients but one were pretreated with enzalutamide or abiraterone. Whole-exome sequencing (WES) of 34 CTC samples, metastasis biopsies, and negative controls were performed for seven patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: WES of CTCs was rigorously qualified in terms of percentage coverage at 10× depth, allelic dropout, and uncovered regions. Shared somatic mutations between CTCs and matched metastasis biopsies were identified. A customized approach based on determination of mutation rates for CTC samples was developed for identification of CTC-exclusive mutations. RESULTS AND LIMITATIONS: Shared mutations were mostly detected in epithelial CTCs and were recurrent. For two patients for whom a deeper analysis was performed, a few CTCs were sufficient to represent half to one-third of the mutations in the matched metastasis biopsy. CTC-exclusive mutations were identified in both epithelial and nonepithelial CTCs and affected cytoskeleton, invasion, DNA repair, and cancer-driver genes. Some 41% of CTC-exclusive mutations had a predicted deleterious impact on protein function. Phylogenic relationships between CTCs with distinct phenotypes were evidenced. CONCLUSIONS: CTCs can provide unique insight into metastasis mutational diversity and reveal undiagnosed genomic aberrations in matched metastasis biopsies. PATIENT SUMMARY: Our results demonstrate the clinical potential of circulating tumor cells to provide insight into metastatic events that could be critical to target using precision medicine.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Faugeroux V, Lefebvre C, Pailler E, et al. An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. Eur Urol Oncol. 2019. PMID: 31412010. doi:10.1016/j.euo.2018.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。